SBI Securities’s Eledon Pharmaceuticals ELDN Stock Holding History

SBI Securities’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248	Hold	63	–	–	﹤0.01%	3261
2026 Q1	$194	Hold	63	–	–	﹤0.01%	3230
2025 Q4	$95	Sell	63 -48	-43%	-$114	﹤0.01%	3420
2025 Q3	$287	Sell	111 -33	-23%	-$96	﹤0.01%	3204
2025 Q2	$390	Buy	144 +140	+3,500%	+$420	﹤0.01%	3067
2025 Q1	$14	Sell	4 -39	-91%	-$160	﹤0.01%	3912
2024 Q4	$177	Buy	+43	New	+$170	﹤0.01%	3282

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

SBI Securities's ELDN Position: Q2 2026 in Review

SBI Securities held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2026 at 63 shares worth $248. The position accounts for ﹤0.01% of the portfolio, ranked #3261.

SBI Securities first reported a position in ELDN in Q4 2024 and has held it in 7 quarters since. The position peaked at $390 in Q2 2025. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

SBI Securities held 63 shares of Eledon Pharmaceuticals worth $248 as of Q2 2026.
SBI Securities left its Eledon Pharmaceuticals share count unchanged in Q2 2026.
Eledon Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3261 holding.
SBI Securities first reported a position in Eledon Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
SBI Securities's Eledon Pharmaceuticals position peaked at $390 in Q2 2025.
160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.